Project Grant K08CA285941
Award Date
8/1/24
Completion Date
7/31/29
Dollars Obligated
$160K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Madison, WI 53715, USA
Similar Awards
This $1,220,394 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support a comprehensive investigation into the acute and chronic neurological side effects of chimeric antigen receptor (CAR) T-cell therapy. The research team at Sloan-Kettering Institute for Cancer Research will conduct a multi-faceted study to characterize the molecular mechanisms, biomarkers, and neurological outcomes associated with immune effector cell-associated...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $600,079 to The Washington University in St. Louis to develop and evaluate a novel combination therapy for relapsed and refractory neuroblastoma, the most common extracranial solid cancer in children. The researchers will deploy two next-generation targeted radiotherapies - 77Br-MBBG (an auger-emitting norepinephrine transporter ligand) and 227Th-L804-LM3 (a thorium-227 alpha-emitting...
This federal Project Grant award, provided by the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), supports the development of an independent research program focused on evaluating novel cellular therapies to improve outcomes for pediatric patients with high-risk malignancies. The $289,458 award over 5 years (9/1/2024 - 8/31/2029) will enable the principal investigator to: Conduct a Phase I clinical trial evaluating an allogeneic CD19-CAR T-cell product using...
This $132,462 Project Grant awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research conducted by the Fred Hutchinson Cancer Center in Seattle, WA. The goal is to investigate why engineered T cell receptor (TCR-T) therapies form different stem-like reservoirs in tumor-draining lymph nodes compared to endogenous tumor-specific T cells, and whether these reservoirs can be targeted to enhance TCR-T cell efficacy against solid tumors. The project will use...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $720,416 to the Sloan-Kettering Institute for Cancer Research to develop a novel theranostic chimeric antigen receptor (CAR) T-cell therapy for neuroendocrine prostate cancer (NEPC). The key objectives are to evaluate the therapeutic efficacy of DLL3-specific CAR-T cells, create DLL3/PSMA bi-specific CAR-T cells, and validate the ability to track the CAR-T cells and...
This $248,509 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research conducted by The Children's Hospital of Philadelphia (CHOP) to better understand the pathophysiology of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) - severe side effects that can occur with chimeric antigen receptor T-cell (CAR-T) cancer therapies. The key objectives are to: 1) Identify the cellular and...
This Project Grant award, worth $244,839, was issued by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The funding will support research at the University of Virginia (UVA) to investigate the use of magnetic resonance imaging-guided focused ultrasound (MRGFUS) in combination with adoptive cellular immunotherapy (B7-H3-targeted CAR T cells) for the treatment of an aggressive subtype of pediatric medulloblastoma brain cancer, known as...
The National Cancer Institute (NCI) awarded a $195,766 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Yale University to develop a mechano-transduction platform to enhance chimeric antigen receptor (CAR) T-cell therapies for cancer treatment. The project aims to engineer force-sensitive tools that can measure forces along key immune receptors and integrate them into CARs to improve specificity and safety of CAR T-cell therapies, particularly for solid tumors. This innovative approach...
This federal Project Grant award, valued at $627,573 and funded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports research to optimize alpha-emitter radioligand therapy (A-RLT) for neuroendocrine tumors (NETs). The award recipient, the Research Institute at Nationwide Children's Hospital (RINCH), will work to maximize tumor responses and mitigate kidney toxicity associated with A-RLT through a multi-faceted approach. Key components include: 1)...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to enhance the anti-tumor functionality of adoptive cell therapy using T-cells expressing a transgenic T-cell receptor (TCR) or chimeric antigen receptor (CAR). The $647,632 award to the University of California, Los Angeles (UCLA) will explore the use of novel lentiviral vectors that co-deliver tumor antigen-specific TCRs/CARs along with the cytokine tumor necrosis...